Abstracts Archive - Page 1129 of 2607 - ACR Meeting Abstracts

Abstract Number: 2837 • 2019 ACR/ARP Annual Meeting
Asymptomatic Monosodium Urate Crystal Deposition Associates with Increased Expression of Pro-Inflammatory Genes
Gabriela Sandoval-Plata¹, Kevin Morgan ², Tamar Guetta-Baranes ², Ana Valdes ³, Michael Doherty ⁴ and Abhishek Abhishek ⁵, ¹Human Genomics and Molecular Genetics, School of Life Sciences, University of Nottingham / Academic Rheumatolog, School of Medicine, University of Nottingham, Nottingham, England, United Kingdom, ²Human Genomics and Molecular Genetics, School of Life Sciences, University of Nottingham, Nottingham, England, United Kingdom, ³Academic Rheumatology, School of Medicine, University of Nottingham / Nottingham NIHR BRC, Nottingham UK, Nottingham, England, United Kingdom, ⁴Academic Rheumatology, Division of Rheumatology,School of Medicine, University of Nottingham, Nottingham, UKArthritis Research UK Pain Centre, Nottingham, UKNational Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham, UK, Nottingham, England, United Kingdom, ⁵Academic Rheumatology, School of Medicine, University of Nottingham,Nottingham,UK National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham,UK, Nottingham, England, United Kingdom
Background/Purpose: Persistent hyperuricaemia is a prerequisite for gout. However, only 10% of people with hyperuricaemia develop symptomatic gout, whereas 25-35% have asymptomatic monosodium urate (MSU)…
Abstract Number: 2838 • 2019 ACR/ARP Annual Meeting
The First Phase 2a Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout
Tim Jansen¹, Viola Kluck ², Matthijs Janssen ³, Antoaneta Comarniceanu ³, Monique Efdé ³, Curtis Scribner ⁴, Damaris Skouras ⁵, Charles Dinarello ⁶ and Leo Joosten ⁷, ¹Viecuri MC, Venlo, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³VieCuri Medical Center, Venlo, Netherlands, ⁴Olatec Therapeutics LLC, New York, ⁵Olatec Therapeutics LLC, New York, NY, ⁶University of Colorado Denver, Aurora, CO, ⁷Department of Internal Medicine and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Acute gout is a severe debilitating type of arthritis that is treated in the acute phase with potent anti-inflammatory drugs. To date, prednisolone, colchicine…
Abstract Number: 2839 • 2019 ACR/ARP Annual Meeting
Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts
Nicholas Sumpter¹, Tony Merriman ², Richard Reynolds ³, Abhishek Abhishek ⁴, Mariano Andrés ⁵, Nicola Dalbeth ⁶, Michael Doherty ⁴, Lennart Jacobsson ⁷, Matthijs Janssen ⁸, Tim Jansen ⁹, Leo Joosten ¹⁰, Meliha Kapetanovic ¹¹, Frédéric Lioté ¹², Hirotaka Matsuo ¹³, Geraldine McCarthy ¹⁴, Fernando Perez-Ruiz ¹⁵, Philip Riches ¹⁶, Pascal Richette ¹⁷, Edward Roddy ¹⁸, Blanka Stiburkova ¹⁹, Alex So ²⁰, Lisa Stamp ²¹, Anne-Kathrin Tausche ²², Rosa Torres-Jimenez ²³ and Till Uhlig ²⁴, ¹University of Otago, Birmingham, ²University of Otago, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Nottingham, Nottingham, United Kingdom, ⁵Hospital General Universitario de Alicante, Alicante, Spain, ⁶University of Auckland, Auckland, New Zealand, ⁷Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁸Rijnstate Hospital, Arnhem, Netherlands, ⁹Viecuri MC, Venlo, Netherlands, ¹⁰Department of Internal Medicine and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands, ¹¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ¹²Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France, ¹³National Defense Medical College, Tokorozawa, Japan, ¹⁴University College Dublin, Dublin, Ireland, ¹⁵Hospital de Cruces, Vizcaya, Spain, ¹⁶The University of Edinburgh, Edinburgh, United Kingdom, ¹⁷Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ¹⁸Research Institute for Primary Care and Health Sciences and Keele Clinical Trials Unit, Keele, United Kingdom, ¹⁹Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic, ²⁰Universite de Lausanne, Lausanne, Switzerland, ²¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²²Universitatsklinikum Dresden, Dresden, Germany, ²³Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Spain, ²⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway
Background/Purpose: This study aimed to determine whether a polygenic risk score (PRS) based on gout-associated genetic variants is associated with gout disease severity phenotypes such…
Abstract Number: 2840 • 2019 ACR/ARP Annual Meeting
Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy
Didem Saygin¹, Chester Oddis ¹, Nicole Neiman ¹, Diane Koontz ¹, Siamak Moghadam-Kia ¹ and Rohit Aggarwal ¹, ¹University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare, debilitating systemic diseases characterized by proximal muscle weakness, which limit activities of daily living and…
Abstract Number: 2841 • 2019 ACR/ARP Annual Meeting
A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
Yoo Jung Kim¹, Elena Schiopu ², Katalin Dankó ³, Tahseen Mozaffar ⁴, Srinivas Chunduru ⁵, Kirstin Lees ⁶, Namita Goyal ⁴, David Fiorentino ⁷ and Kavita Sarin ⁷, ¹Stanford University School of Medicine, Redwood City, CA, ²Department of Rheumatology, University of Michigan, Ann Arbor, ³Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary, ⁴Department of Neurology, University of California Irvine, Irvine, CA, ⁵Idera Pharmaceuticals, Inc., Cambridge, MA, ⁶Idera Pharmaceuticals, Inc., Cambridge, ⁷Department of Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a rare inflammatory disease of skin and muscle associated with characteristic skin findings, muscle weakness, interstitial lung disease, pruritus, and malignancies.…
Abstract Number: 2842 • 2019 ACR/ARP Annual Meeting
Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control
Sangmee Bae¹, Ilana Golub ², Jennifer Wang ³, Ani Shahbazian ², Srinivasa Reddy ³ and Christina Charles-Schoeman ⁴, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Medical Center, Los Angeles, ⁴University of California, Los Angeles, CA
Background/Purpose: Inflammation and damage to the vascular endothelium are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis. Paraoxonase 1 (PON1) is a…
Abstract Number: 2843 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Victoria Werth¹, David Pearson ², Joyce Okawa ², Rui Feng ³, Josef Concha ², Basil Patel ², Emily Hejazi ², Scott Constantine ⁴, Nancy Dgetluck ⁴ and Barbara White ⁴, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Philadelphia Veteran Affairs Medical Center, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Lenabasum is a rationally-designed preferential cannabinoid receptor type 2 agonist that activates resolution of innate immune responses to reduce tissue inflammation and fibrotic processes.…
Abstract Number: 2844 • 2019 ACR/ARP Annual Meeting
Predictive Factors for Mortality in Anti-melanoma-associated Gene 5 Antibody-associated Interstitial Lung Disease
Takahisa Gono¹, Kenichi Masui ², Naoshi Nishina ³, Shinji Sato ⁴ and Masataka Kuwana ⁵, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ²Department of Anaesthesiology, Show University School of Medicine, Saitama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is useful to predict mortality in patients with myositis–associated interstitial lung disease (ILD) because of high prevalence of…
Abstract Number: 2845 • 2019 ACR/ARP Annual Meeting
Pain Patterns in Idiopathic Inflammatory Myopathy (IIM): Associations with Disease Activity Measures (Muscle Enzymes, Manual Muscle Testing 8), Patient-Reported Quality of Life (HAQ) and Pain Scales (Widespread Pain Index (WPI), Symptom Severity Index (SSI) and Visual Analogue Scale)
Elena Schiopu¹, Sohail Farshad ², Nada Abdulaziz ³, Stacey Anderson ³ and Ann Impens ⁴, ¹Department of Rheumatology, University of Michigan, Ann Arbor, ²Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, ³The University of Michigan, Ann Arbor, MI, ⁴Institute for Healthcare Innovation, Glendale, AZ
Background/Purpose: IIMs associate with significant lifelong disability due to progressive loss of muscle function and lack of curative interventions; little is known about the relative…
Abstract Number: 2846 • 2019 ACR/ARP Annual Meeting
Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)
Nathalie Carrier ¹, Sophie Roux ², Ariel Masetto ², Artur deBrum Fernandes ², Patrick Liang ², Meryem Maoui ³ and Gilles Boire², ¹CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Bristol-Myers Squibb Canada, St-Laurent, QC, Canada
Background/Purpose: To analyze the evolution over 20 years of disease activity, treatments and radiographic progression over the first 5 years of follow up of patients…
Abstract Number: 2847 • 2019 ACR/ARP Annual Meeting
Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA
Paul Studenic¹, David Felson ², Maarten de Wit ³, Farideh Alasti ⁴, Tanja Stamm ¹, Josef Smolen ¹ and Daniel Aletaha ¹, ¹Medical University of Vienna, Vienna, Austria, ²Boston University School of Medicine, Department of Rheumatology, Boston, ³Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁴Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria
Background/Purpose: The patient global assessment (PGA) is a core set variable to assess RA disease activity. It is strongly linked to patient-reported pain and is…
Abstract Number: 2848 • 2019 ACR/ARP Annual Meeting
Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)
Stefano Alivernini¹, Barbara Tolusso ¹, Marco Gessi ², Maria Rita Gigante ¹, Luca Petricca ¹, Clara Di Mario ³, Simone Perniola ¹, Anna Laura Fedele ¹, Giusy Peluso ⁴, Laura Bui ², Annunziata Capacci ¹, Francesco Federico ², Gianfranco Ferraccioli ³ and Elisa Gremese ¹, ¹Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, ⁴Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy, Italy
Background/Purpose: Ultrasound (US)-guided minimally-invasive Synovial Tissue (ST) biopsy is a well tolerated procedure for basic and translational studies on chronic inflammatory joint diseases as Rheumatoid…
Abstract Number: 2849 • 2019 ACR/ARP Annual Meeting
Radiographic Progression During a 10-Year Follow-Up : Results from the French Cohort ESPOIR
Joanna Kedra¹, David Hajage ², Alexandre Lafourcade ², Bernard Combe ³, Maxime Dougados ⁴ and Bruno Fautrel ⁵, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴Cochin Hospital, Paris, France, ⁵Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: In early arthritis, identification of patients at risk of developing joint damage is an important issue. In rheumatoid arthritis (RA), the rate of progression…
Abstract Number: 2850 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry
Jeffrey Curtis¹, Michael Weinblatt ², Kenneth Saag ¹, Vivian Bykerk ³, Christina Charles-Schoeman ⁴, Stefano Fiore ⁵, Gregory St John ⁶, Toshio Kimura ⁷, Shen Zheng ⁵, Clifton Bingham ⁸, Grace Wright ⁹, Martin Bergman ¹⁰, Kamala Nola ¹¹, Daniel Furst ⁴ and Nancy Shadick ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Brigham and Women's Hospital, Boston, MA, ³Hospital for Special Surgery, New York City, NY, ⁴University of California, Los Angeles, CA, ⁵Sanofi Genzyme, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁸Johns Hopkins University, Baltimore, MD, ⁹Private Practice, New York City, NY, ¹⁰Drexel University College of Medicine, Stockholm, Sweden, ¹¹Lipscomb University College of Pharmacy & Health Sciences, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) may share characteristics that relate to their future outcomes. We investigated clinical outcomes over a 4-year follow-up period in…
Abstract Number: 2851 • 2019 ACR/ARP Annual Meeting
Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations
Nina Sundlisater¹, Anna-Birgitte Aga ², Ulf Sundin ³, Hilde Hammer ¹, Till Uhlig ⁴, Tore Kvien ⁴, Espen Haavardsholm ⁴ and Siri Lillegraven ⁵, ¹Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ³Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway
Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].